Novel Biology or Therapeutic Compounds for Treatment of Immunology & Inflammation Diseases

A multinational pharmaceutical company is seeking novel biology or therapeutic compounds for the treatment of Immunology & Inflammation (I&I) diseases, such as asthma and chronic obstructive pulmonary disorder (COPD). The team is particularly interested in approaches that have a novel mechanism of action for these diseases with no therapeutics currently in the clinic acting on the same target, however differentiated modalities for known targets are also of interest (e.g. small molecule or oral peptides for validated targets with biologics).

Approaches of Interest:

• Novel first-in-class or best-in-class therapeutics for I&I diseases
• Targets and therapeutics for asthma, COPD and inflammatory bowel disease (IBD) are of particular interest, however other I&I conditions are also considered
• Small molecule, large molecule, and RNA modalities are of highest interest
• Chemical compound, sRNA and CRISPR libraries of therapeutics for I&I diseases are also relevant

Out of Scope:

• Drug repurposing approaches
• Natural products and herbal medicine

Developmental Stages of Interest:

• With compounds, opportunities from the preclinical research phase to phase 2 are within scope, provided there is experimental proof of concept for the target/therapeutic
• Without compounds, opportunities with preliminary target validation including in vivo validation are of highest interest, although opportunities with only in vitro validation will still be considered

Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications. It would be extremely helpful if targets, related diseases, IP status, associated spinouts, and competition landscape are included. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.